Idexx Laboratories (IX1) AI Stock Analysis

Idexx Laboratories

(XETRA:IX1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring diagnostics growthStrong recurring diagnostic growth demonstrates durable demand beyond clinic visit volumes and supports predictable revenue from consumables and services. The premium to U.S. visit trends also indicates effective pricing, workflow integration, and customer retention.

Negative Factors

U.S. visit pressurePersistent declines in U.S. clinical and wellness visits can constrain test volumes and slow growth in visit-linked services. Continued consumer pressure and slower pet additions may delay volume recovery, even if IDEXX retains share and gains pricing.

Idexx Laboratories (IX1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 43.42B
Dividend Yield: ―
Average Volume (3M): 14
Price to Earnings (P/E): 38.7
Beta (1Y): 0.72
Revenue Growth: 5.23%
EPS Growth: 10.48%
Country: Germany
Employees: 11,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Idexx Laboratories Business Overview & Revenue Model

Company Description

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dair...

Idexx Laboratories Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:-0.63%|Next Earnings Date:Nov 01, 2026

Earnings Call SentimentPositive

The call conveyed a strongly constructive operational and financial picture: solid organic revenue growth (~9% Q2), recurring CAG Diagnostics strength, robust margin and EPS expansion, strong free cash flow and aggressive capital returns, plus clear product and innovation momentum (inVue Dx, Cancer Dx, Catalyst SDMA). Offsetting items include continued pressure on U.S. clinic and wellness visits, a Q2 instrument revenue lap effect, foreign-exchange headwinds, and planned incremental investments that will temper near-term margin gains. Overall, the positive drivers — durable recurring revenue expansion, margin gains, cash generation, and multiple innovation milestones — materially outweigh the cited headwinds.

Positive Updates

Strong Revenue and Upgraded Full-Year Outlook

Q2 revenue increased ~10% reported and ~9% organically. Company updated full-year revenue guidance to $4,700M–$4,745M (midpoint raised $5M net), with an overall organic revenue growth outlook of 8.5%–9.7% and reported revenue growth of ~9.1%–10.3%.

Negative Updates

Decline in U.S. Clinical and Wellness Visits

U.S. same-store clinical visits declined ~1.3% in Q2. Wellness visits were a primary constraint and were down in the mid-single digits (reference lab wellness noted as down ~3.4% in the U.S.), driven by discretionary spending pressure and a muted puppy adoption cadence.

Company Guidance

IDEXX raised its 2026 outlook to $4,700–$4,745 million in revenue (≈$5M increase at midpoint, reflecting a $20M operational improvement offset by a $15M FX headwind), implying reported revenue growth of 9.1%–10.3% and overall organic revenue growth of 8.5%–9.7%; organic CAG Diagnostics recurring revenue is guided to 9.5%–10.7% (including ~4% net price realization). Full‑year EPS is now $14.69–$14.94 (up $0.14 at midpoint), a 13%–15% comparable EPS growth range (EPS includes a $0.05 share‑based compensation benefit and a $0.05 FX headwind), and a 1% USD strengthening would cut revenue by ≈$8M and EPS by ≈$0.03. Reported operating margin is expected at 32.3%–32.5% with 70–90 bps of comparable operating margin improvement for the year; Q3 margins are guided to 32.5%–32.8% with a 20–50 bps comparable expansion. Free cash flow conversion is raised to 90%–100% of net income (capex ≈$180M); Q2 FCF was $323M, H1 FCF $557M, trailing‑12‑month conversion 110%. Leverage finished the quarter ~0.6x gross/0.5x net; share repurchases totaled $332M in Q2 and $693M YTD, reducing diluted shares by ~2% Y/Y; management expects ~1.5% U.S. clinical visit declines in 2H at midpoint.

Idexx Laboratories Risk Analysis

Idexx Laboratories disclosed 24 risk factors in its most recent earnings report. Idexx Laboratories reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Idexx Laboratories Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:IX1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMO	77Outperform	$257.71B	36.70	13.31%	0.26%	8.27%	9.59%
ILMN	76Outperform	$35.63B	40.07	31.45%	―	6.00%	31.48%
A	75Outperform	$49.30B	34.35	20.47%	0.58%	8.60%	19.07%
DHR	73Outperform	$163.38B	37.95	8.18%	0.65%	5.52%	25.53%
WAT	57Neutral	$45.46B	115.10	1.88%	―	52.47%	-63.86%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:IX1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IX1	Idexx Laboratories	489.00	-130.60	-21.08%
A	Agilent Technologies	174.87	31.26	21.77%
DHR	Danaher Corporation	232.23	19.74	9.29%
ILMN	Illumina	235.99	116.00	96.67%
TMO	Thermo Fisher Scientific	697.00	134.10	23.82%
WAT	Waters Corp	462.72	117.13	33.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Idexx Laboratories AI Stock Analysis